Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. VORAXAZE (glucarpidase)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

VORAXAZE (glucarpidase)

Medicine - Posted on Aug 22 2024 - Updated on Mar 05 2025
Active substance (DCI)
  • glucarpidase
history (3)
  • 3/30/23

    VORAXAZE (glucarpidase) - Intoxication au méthotrexate

    Autorisation d’accès précoce renouvelée de la spécialité VORAXAZE (glucarpidase) dans l’indication « réduction de la concent...
    icône flèche
  • 7/20/22

    VORAXAZE (Glucarpidase) - réduction de la concentration plasmatique toxique de méthotrexate

    Key points Favourable opinion for reimbursement as treatment to reduce toxic plasma methotrexate concentration in adults and...
    CAV :
    54321
    icône flèche
  • 4/25/22

    VORAXAZE (glucarpidase)

    Autorisation d’accès précoce octroyée à la spécialité VORAXAZE (glucarpidase) dans l’indication « réduire la concentration p...
    icône flèche
Technical information
ATC code
  • V03AF09
Manufacturer
SERB SAS
Presentation

VORAXAZE (glucarpidase) - Poudre pour solution pour injection
1 flacon de 1000 unités (UCD : 34008 9299213 6) - (Code CIP : 34009 550 880 9 7)

All our publications
    Autoimmune diseases Drug therapy Joint and rheumatic diseases Paediatrics Poisoning Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
FH4wpTFS69F6hFRY